Cefepime/sulbactam

Cefepime/sulbactam
Combination of
CefepimeCephalosporin
Sulbactamβ-Lactamase inhibitor
Clinical data
Trade namesMaxictam-AF
Legal status
Legal status
  • Rx in several countries

Cefepime/sulbactam is a 1:1 fixed-dose combination of cefepime (a fourth-generation cephalosporin) and sulbactam (a β-lactamase inhibitor). The combination exerts a bactericidal effect by disrupting bacterial cell wall synthesis through transpeptidase inhibition, thereby impairing peptidoglycan cross-linking. It was developed in 2006 by Russian researchers.

Cefepime/sulbactam was approved for medical use in Russia in 2019 and is also registered in Belarus, Armenia, Azerbaijan, Uzbekistan, Kyrgyzstan and Mongolia under the trade name Maxictam-AF.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.